Combining mAb and vaccines comprising long-peptides of known melanoma- or melanocyte-associated antigens, such as gp100 and the tumour-differentiation antigens tyrosinase-related proteins (TRP)-1 and TRP-2 has been studied. Here, PMEL is linked to melanoma.